3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There is limited evidence on the blood pressure (BP)-lowering effect of esaxerenone on home BP, including nighttime BP. Using two newly developed nocturnal home BP monitoring devices (brachial and wrist), this multicenter, open-label, prospective study investigated the nighttime home BP-lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension being treated with an angiotensin receptor blocker (ARB) or calcium-channel blocker (CCB). In total, 101 patients were enrolled. During the 12-week study period, change in nighttime home systolic/diastolic BP from baseline to end of treatment measured by the brachial device was −12.9/−5.4 mmHg in the total population and −16.2/−6.6 and −10.0/−4.4 mmHg in the ARB and CCB subcohorts, respectively (all p < 0.001). For the wrist device, the change was −11.7/−5.4 mmHg in the total population and −14.6/−6.2 and −8.3/−4.5 mmHg in each subcohort, respectively (all p < 0.001). Similar significant reductions were shown for morning and bedtime home BP and office BP. Urinary albumin-to-creatinine ratio, N-terminal pro-brain natriuretic peptide, and cardio-ankle vascular index improved in the total population and each subcohort. Incidences of treatment-emergent adverse events (TEAEs) and drug-related TEAEs were 38.6% and 16.8%, respectively; most were mild or moderate. The most frequent drug-related TEAEs were associated with serum potassium elevation (hyperkalemia, 9.9%; blood potassium increased, 3.0%); however, no new safety concerns were raised. Esaxerenone was effective in lowering nighttime home BP as well as morning and bedtime home BP and office BP, safe, and showed organ-protective effects in patients with uncontrolled nocturnal hypertension. Caution is warranted regarding elevated serum potassium levels.

          This study investigated the effect of esaxerenone on nighttime home BP and organ damage (UACR and NT-proBNP) in patients with uncontrolled nocturnal hypertension despite treatment with an ARB or CCB. Our results show that safe 24-h BP control and organ protection are possible with esaxerenone.

          Abstract

          This study investigated the effect of esaxerenone on nighttime home BP and organ damage (UACR and NT-proBNP) in patients with uncontrolled nocturnal hypertension despite treatment with an ARB or CCB. Our results show that safe 24-h BP control and organ protection are possible with esaxerenone.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: not found
          • Article: not found

          The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

            Change in albuminuria has strong biological plausibility as a surrogate endpoint for progression of chronic kidney disease, but empirical evidence to support its validity is lacking. We aimed to determine the association between treatment effects on early changes in albuminuria and treatment effects on clinical endpoints and surrograte endpoints, to inform the use of albuminuria as a surrogate endpoint in future randomised controlled trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

              Change in albuminuria as a surrogate endpoint for progression of chronic kidney disease is strongly supported by biological plausibility, but empirical evidence to support its validity in epidemiological studies is lacking. We aimed to assess the consistency of the association between change in albuminuria and risk of end-stage kidney disease in a large individual participant-level meta-analysis of observational studies.
                Bookmark

                Author and article information

                Contributors
                kkario@jichi.ac.jp
                Journal
                Hypertens Res
                Hypertens Res
                Hypertension Research
                Springer Nature Singapore (Singapore )
                0916-9636
                1348-4214
                12 May 2023
                12 May 2023
                2023
                : 46
                : 7
                : 1782-1794
                Affiliations
                [1 ]GRID grid.410804.9, ISNI 0000000123090000, Division of Cardiovascular Medicine, Department of Medicine, , Jichi Medical University School of Medicine, ; Shimotsuke, Japan
                [2 ]Minamisanriku Hospital, Motoyoshi, Japan
                [3 ]Kato Clinic of Internal Medicine, Tokyo, Japan
                [4 ]Kashinoki Internal Medicine, Date, Japan
                [5 ]Uchiyama Clinic, Joetsu, Japan
                [6 ]GRID grid.414157.2, ISNI 0000 0004 0377 7325, Department of Cardiology, , Hiroshima City Asa Hospital, ; Hiroshima, Japan
                [7 ]Takahashi Family Clinic, Nagoya, Japan
                [8 ]Tsuruma Kaneshiro Diabetes Clinic, Yamato, Japan
                [9 ]GRID grid.518308.7, Shiraiwa Medical Clinic, ; Kashiwara, Japan
                [10 ]Department of Cardiovascular Medicine, Onga Nakama Medical Association Onga Hospital, Onga, Japan
                [11 ]GRID grid.410844.d, ISNI 0000 0004 4911 4738, Primary Medical Science Department, , Daiichi Sankyo Co., Ltd., ; Tokyo, Japan
                [12 ]GRID grid.410844.d, ISNI 0000 0004 4911 4738, Data Intelligence Department, , Daiichi Sankyo Co., Ltd., ; Tokyo, Japan
                Article
                1292
                10.1038/s41440-023-01292-0
                10319630
                37173430
                1d4e3391-e630-4920-a1e2-458b3e493297
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 30 November 2022
                : 3 April 2023
                : 4 April 2023
                Categories
                Article
                Custom metadata
                © The Japanese Society of Hypertension 2023

                Cardiovascular Medicine
                esaxerenone,home blood pressure,mineralocorticoid receptor blocker,nocturnal hypertension,uncontrolled hypertension

                Comments

                Comment on this article